US Stock Market Move | HUTCHMED (HCM.US) rises over 3% after submitting an NDA to the FDA for the ORPATHYS plus TAGRISSO combination therapy.
On Wednesday, HUTCHMED (HCM.US) rose over 3% to $14.59.
On Wednesday, HUTCHMED (HCM.US) rose over 3% to $14.59. On the news front, on September 29, HUTCHMED announced that Astrazeneca PLC Sponsored ADR has submitted a New Drug Application to the U.S. FDA for the combination therapy of ORPATHYS and TAGRISSO, for the treatment of patients with locally advanced or metastatic non-small cell lung cancer with MET overexpression or amplification who have experienced disease progression during or after treatment with an EGFR TKI. The SAFFRON global Phase III study showed that the combination therapy demonstrated improvements in both progression-free survival and overall survival.
Related Articles
Zelgen Biopharmaceutical (688266.SH): New Drug Application for Gecacitinib Hydrochloride Tablets for the Treatment of Active Ankylosing Spondylitis Accepted
Services and wealth management businesses become key "engine"! Citigroup (C.US) Q3 net profit surges 40% year-over-year, EPS beats expectations.
Tower Semiconductor Ltd(TSEM.US) and Semtech Corporation(SMTC.US) Expand Collaboration to Secure Silicon Germanium Capacity for AI Data Center Connectivity
Zelgen Biopharmaceutical (688266.SH): New Drug Application for Gecacitinib Hydrochloride Tablets for the Treatment of Active Ankylosing Spondylitis Accepted
Services and wealth management businesses become key "engine"! Citigroup (C.US) Q3 net profit surges 40% year-over-year, EPS beats expectations.
Tower Semiconductor Ltd(TSEM.US) and Semtech Corporation(SMTC.US) Expand Collaboration to Secure Silicon Germanium Capacity for AI Data Center Connectivity
